Truist lowered the firm’s price target on Intuitive Surgical to $320 from $400 and keeps a Buy rating on the shares as part of a broader research note on MedTech. The sector continues to trade down on fear of exposure to GLP-1s, and even good Q3 earnings may not matter amid a GLP-1 sector overhang, the analyst tells investors in a research note. While Truist continues to believe that the dramatic GLP1-driven sector pullback is likely overdone and that “narrative” is driving indiscriminate selling more so than a tangible fundamental impact, it’s hard to say when/if the GLP-1 overhang will subside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ISRG:
- Intuitive Surgical call volume above normal and directionally bullish
- Intuitive Surgical price target lowered to $350 from $365 at JPMorgan
- Intuitive Surgical added to ‘Tactical Underperform’ list at Evercore ISI
- LLY, ISRG, or JNJ: Which Healthcare Stock Could Generate the Best Returns?
- Early notable gainers among liquid option names on September 18th